Demo
KALV Nasdaq· KalVista Pharmaceuticals Inc.
FundamentalsNews digest Peer analysis
Login
KALV Nasdaq· KalVista Pharmaceuticals Inc.
Earnings report Q1 2024

KALV's Revenue Remains Flat in Latest Quarter

Segments of revenue

KALV's revenue for the quarter ending January 31, 2024, remained stagnant at $0, mirroring the same figure from the previous year.

Strengths

Despite the lack of revenue, KALV managed to generate some income through other avenues. The firm saw an increase in interest income, which rose from $732,000 to $684,000. Additionally, the company experienced a foreign currency exchange gain of $1.12 million, up from $597,000 in the previous year.

Challenges

The primary challenge for KALV is the absence of revenue generation. The company's operating expenses, including research and development and general and administrative expenses, have increased. Research and development expenses rose from $20.06 million to $22.52 million, while general and administrative expenses increased from $6.88 million to $10.63 million. This resulted in an operating loss of $33.15 million, up from $26.95 million in the previous year.

Noteworthy

The company's net loss for the quarter was $29.03 million, a significant increase from the $21.3 million loss reported in the same period last year.

Summary

KALV's latest quarter was marked by a lack of revenue, increased operating expenses, and a larger net loss compared to the previous year. While the company managed to generate some income through interest and foreign currency exchange gains, these were not enough to offset the increased expenses and absence of revenue. The firm's financial performance indicates a need for strategies to boost revenue and control expenses.

Source documents

Form 10-Q  filed on Mar 11, 2024
37 pages scanned

Reference data

Company financials Q1 revenue 0
Analyst estimates Q1 EPS beat by 7.23%
Sign up to Fey

Get in-depth analysis on thousands of stocks for just $30/month. Cancel anytime.